Eleonora Scorletti Selected Research

Omacor

1/2018	Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis severity in NAFLD.
3/2016	Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
1/2016	Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.
8/2015	Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial.
10/2014	Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eleonora Scorletti Research Topics

Disease

22	Non-alcoholic Fatty Liver Disease 01/2022 - 08/2013
6	Fatty Liver 06/2019 - 08/2015
5	Liver Cirrhosis (Hepatic Cirrhosis) 10/2021 - 10/2014
5	Fibrosis (Cirrhosis) 10/2021 - 01/2018
4	Liver Diseases (Liver Disease) 12/2018 - 12/2015
3	Type 2 Diabetes Mellitus (MODY) 12/2020 - 01/2016
3	Alcoholic Fatty Liver 10/2020 - 01/2017
3	Inflammation (Inflammations) 12/2018 - 03/2016
2	Hepatocellular Carcinoma (Hepatoma) 10/2020 - 01/2016
2	Insulin Resistance 01/2020 - 08/2013
2	Cardiovascular Diseases (Cardiovascular Disease) 10/2019 - 03/2016
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 01/2022
1	Overweight 01/2022
1	Glucose Intolerance 01/2020
1	Hyperemia 01/2020
1	Neoplasms (Cancer) 10/2019
1	Weight Loss (Weight Reduction) 01/2016
1	End Stage Liver Disease 01/2016
1	Hepatitis C 01/2016
1	Arterial Occlusive Diseases (Arterial Occlusive Disease) 08/2015
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2013

Drug/Important Bio-Agent (IBA)

6	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2019 - 08/2015
5	Omacor FDA Link 01/2018 - 10/2014
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 10/2014
3	Triglycerides (Triacylglycerol)IBA 06/2019 - 12/2015
3	AcidsIBA 01/2019 - 08/2015
3	Eicosapentaenoic AcidIBA 12/2018 - 10/2014
2	PrebioticsIBA 01/2020 - 01/2018
2	Biological ProductsIBA 12/2018 - 08/2013
2	LipidsIBA 12/2018 - 01/2016
2	FructoseIBA 01/2018 - 01/2017
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 12/2015
2	Uric Acid (Urate)IBA 01/2018 - 01/2017
1	Vitamin E FDA LinkGeneric 01/2022
1	Growth Differentiation Factor 15IBA 10/2021
1	TransferasesIBA 12/2020
1	CeramidesIBA 01/2020
1	oxidized low density lipoproteinIBA 10/2019
1	LDL CholesterolIBA 10/2019
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2019
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2019
1	ProteomeIBA 01/2019
1	AntioxidantsIBA 01/2018
1	obeticholic acidIBA 01/2018
1	Bile Acids and Salts (Bile Acids)IBA 01/2018
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2018
1	Keratin-18 (Keratin 18)IBA 03/2016
1	Therapeutic UsesIBA 01/2016
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2016
1	Phospholipases (Phospholipase)IBA 12/2015
1	acivicin (AT 125)IBA 08/2015
1	Docosahexaenoic AcidsIBA 10/2014
1	Cholecalciferol (Vitamin D3)FDA Link 08/2013
1	Insulin (Novolin)FDA Link 08/2013
1	CollagenIBA 08/2013
1	CytokinesIBA 08/2013
1	AnticoagulantsIBA 08/2013
1	Calcifediol (Calcidiol)FDA Link 08/2013

Therapy/Procedure

6	Therapeutics 06/2019 - 08/2015
3	Liver Transplantation 10/2020 - 01/2016
2	Lasers (Laser) 01/2020 - 01/2019